A Szmulewicz1, C E Millett2, M Shanahan3, F M Gunning4, K E Burdick5. 1. Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, United States. 2. Mood and Psychosis Research Program, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, United States; Department of Psychiatry, Harvard Medical School, Boston, MA, United States. 3. Mood and Psychosis Research Program, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, United States. 4. Department of Psychiatry, Weill Cornell Medicine, New York, NY, United States. 5. Mood and Psychosis Research Program, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, United States; Department of Psychiatry, Harvard Medical School, Boston, MA, United States. Electronic address: kburdick1@bwh.harvard.edu.
Abstract
BACKGROUND: Evidence regarding the performance of Bipolar Disorder patients (BD) on Emotional Processing (EP) is conflicting, suggesting that heterogeneity within this population may exist. It is not completely understood if this impacts on clinical presentation and functional outcomes. METHODS: A total of 212 BD patients were recruited. Patients underwent MATRICS Consensus Cognitive Battery as well as a clinical evaluation to detect premorbid traits, comorbidities and clinical features. Performance on each basic emotion on the Emotional Recognition Task (ERT) and Reading the Mind in the Eyes Test were entered into hierarchical cluster analyses in order to determine the number of clusters and to assign subjects to specific clusters. We then compared subgroups on clinical factors and real-world community functioning. RESULTS: No differences between BD patients as a group and controls were found in EP performance. Two clusters of BD patients were found, one with "intact" performance (71.2%) that performed as healthy controls (HC) and other with "impaired" performance (28.8%) performing worse than HC and schizophrenic patients on basic emotion recognition. Patients in the "impaired group" presented higher rates of childhood trauma, schizotypal traits, lower premorbid IQ and education, poor psychosocial functioning and cognitive performance. LIMITATIONS: Cross-sectional data which limits our ability to infer directionality of our findings. CONCLUSION: These results suggest the presence of two subgroups regarding EP performance with unique clinical and neurodevelopmental profiles associated. Next steps will include using these data to identify a homogeneous group of patients to target these disabling symptoms with treatment.
BACKGROUND: Evidence regarding the performance of Bipolar Disorderpatients (BD) on Emotional Processing (EP) is conflicting, suggesting that heterogeneity within this population may exist. It is not completely understood if this impacts on clinical presentation and functional outcomes. METHODS: A total of 212 BD patients were recruited. Patients underwent MATRICS Consensus Cognitive Battery as well as a clinical evaluation to detect premorbid traits, comorbidities and clinical features. Performance on each basic emotion on the Emotional Recognition Task (ERT) and Reading the Mind in the Eyes Test were entered into hierarchical cluster analyses in order to determine the number of clusters and to assign subjects to specific clusters. We then compared subgroups on clinical factors and real-world community functioning. RESULTS: No differences between BD patients as a group and controls were found in EP performance. Two clusters of BD patients were found, one with "intact" performance (71.2%) that performed as healthy controls (HC) and other with "impaired" performance (28.8%) performing worse than HC and schizophrenicpatients on basic emotion recognition. Patients in the "impaired group" presented higher rates of childhood trauma, schizotypal traits, lower premorbid IQ and education, poor psychosocial functioning and cognitive performance. LIMITATIONS: Cross-sectional data which limits our ability to infer directionality of our findings. CONCLUSION: These results suggest the presence of two subgroups regarding EP performance with unique clinical and neurodevelopmental profiles associated. Next steps will include using these data to identify a homogeneous group of patients to target these disabling symptoms with treatment.
Authors: Yann Quidé; Leonardo Tozzi; Mark Corcoran; Dara M Cannon; Maria R Dauvermann Journal: Neuropsychiatr Dis Treat Date: 2020-12-14 Impact factor: 2.570